Resverlogix Equity Warrants Exp 30 May 2023 RVX"A-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 05/11/22 EDT
0.11UNCH (UNCH)
52 week range
0.05 - 0.48
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.11
  • 52 Week High0.48
  • 52 Week High Date02/03/22
  • 52 Week Low0.05
  • 52 Week Low Date10/08/21

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.11
  • 52 Week High0.48
  • 52 Week High Date02/03/22
  • 52 Week Low0.05
  • 52 Week Low Date10/08/21
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Resverlogix Equity Warrants Exp 30 May 2023

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Resverlogix Corp. is a Canada-based clinical biotechnology company that is focused on improving the lives of patients with chronic illnesses. The Company is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective...
Donald Mccaffrey
Chairman of the Board, President, Chief Executive Officer, Secretary
A. Brad Cann CPA
Chief Financial Officer
Address
300-4820 Richard Rd SW
Calgary, AB
T3E 6L1
Canada